Orchid Pharma Ltd Q4 FY26 Results

Summary

Orchid Pharma Limited reported mixed financial results for Q4 and the full financial year ended March 31, 2026. While standalone net sales remained flat year-over-year at ₹23,760.73 lakhs for Q4 FY26, and standalone Profit Before Tax (PBT) increased by 9.89% to ₹3,060.37 lakhs, the full fiscal year saw a substantial decline. For FY26, standalone net sales decreased by 12.00% to ₹81,132.73 lakhs, with standalone PBT falling significantly by 57.54% to ₹4,520.79 lakhs. Consolidated PBT also experienced a dramatic 92.42% drop for FY26, settling at just ₹53.92 lakhs, and the auditors issued a modified opinion on the consolidated financial results.

Key Highlights

1. 1

   Orchid Pharma Limited's standalone net sales for the quarter ended March 31, 2026 (Q4 FY26) were ₹23,760.73 lakhs, a marginal increase of 0.05% compared to ₹23,747.87 lakhs in Q4 FY25.

2. 2

   The standalone Profit Before Tax (PBT) for Q4 FY26 increased by 9.89% to ₹3,060.37 lakhs from ₹2,784.87 lakhs in the corresponding quarter of the previous year.

3. 3

   For the full financial year ended March 31, 2026 (FY26), standalone net sales decreased by 12.00% to ₹81,132.73 lakhs, down from ₹92,192.59 lakhs in FY25.

4. 4

   Standalone PBT for FY26 saw a significant decline of 57.54%, falling to ₹4,520.79 lakhs from ₹10,648.34 lakhs in the prior fiscal year.

5. 5

   On a consolidated basis, Profit Before Tax (PBT) for Q4 FY26 rose by 16.52% to ₹2,224.76 lakhs, compared to ₹1,909.41 lakhs in Q4 FY25.

6. 6

   However, consolidated PBT for the full FY26 dramatically plummeted by 92.42% to ₹53.92 lakhs, a sharp drop from ₹711.27 lakhs reported in FY25.

7. 7

   The company's consolidated financial results for FY26 were accompanied by an auditors' report with a modified opinion, indicating a significant audit qualification.